Hetero Healthcare Limited has announced the launch of Perzea, its most affordable biosimilar of pertuzumab, marking a significant milestone in expanding access to advanced breast cancer treatment in India. The product has been developed through a semi-exclusive collaboration with Enzene Biosciences Limited, targeting the substantial cost barriers that have limited patient access to this critical therapy.
Addressing Treatment Accessibility Challenges
Pertuzumab, a monoclonal antibody, is globally recognized as a standard of care when used in combination with trastuzumab and chemotherapy for treating HER2-positive breast cancer. Despite its proven efficacy, the high cost of treatment has restricted access in India, creating a significant treatment gap for thousands of patients requiring this advanced therapy.
"Our focus has always been to make advanced therapies more accessible without compromising on quality. With Perzea, we take a decisive step towards ensuring that no patient is denied life-saving care due to affordability challenges," said M. Srinivas Reddy, Managing Director of Hetero Healthcare Limited.
Strategic Partnership for Enhanced Access
The collaboration between Hetero Healthcare and Enzene Biosciences represents a strategic approach to democratizing access to advanced cancer therapies. Dr. Himanshu Gadgil, CEO of Enzene Biosciences, emphasized the partnership's significance: "We are proud to partner with Hetero Healthcare in this impactful endeavour. At Enzene, our mission is to leverage cutting-edge technology platforms to deliver high-quality biologics at affordable prices. This collaboration is a reflection of our shared vision to transform cancer care in India."
Enzene Biosciences operates as a fully integrated biologics innovator with its patented EnzeneX™ continuous manufacturing technology, maintaining facilities in Pune, India, and New Jersey, USA. The company focuses on transforming biologics production efficiency and affordability.
Alignment with Healthcare Policy Goals
The launch of Perzea aligns with the Government of India's healthcare vision to ensure equitable access to life-saving medications. This initiative strengthens Hetero Healthcare's legacy of delivering low-cost oncology medicines across critical therapeutic areas, providing renewed hope for breast cancer patients and their families by combining affordability with innovation.
Hetero Healthcare Limited operates as one of India's leading pharmaceutical companies, delivering high-quality medicines across oncology, antiretrovirals, and critical care. The company's patient-centric innovation approach continues to drive better outcomes across India, with a strong commitment to making advanced therapies accessible without compromising quality standards.
Clinical Impact and Treatment Protocol
Perzea is designed to be administered as part of the established treatment protocol for HER2-positive breast cancer, used in combination with trastuzumab and chemotherapy. This targeted therapy approach represents a crucial treatment option for patients with this specific breast cancer subtype, offering the potential for improved outcomes when cost barriers are removed.
The biosimilar launch addresses a critical need in India's oncology landscape, where economic barriers have historically limited patient access to advanced cancer therapies. By providing a more affordable alternative while maintaining therapeutic equivalence, Perzea enables healthcare providers to offer comprehensive treatment options to a broader patient population.
